Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. - Test2 - elhamkhani - TriplyDB

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

http://www.wikidata.org/entity/Q37603371

about

Regulation of glucose homeostasis by GLP-1 Dipeptidyl peptidase-4 and kidney fibrosis in diabetes Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?The Concise Guide to PHARMACOLOGY 2013/14: enzymes.Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance The nonglycemic actions of dipeptidyl peptidase-4 inhibitors Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.Saxagliptin for type 2 diabetes Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.Diabetes: impaired damage control Identification of novel dipeptidyl peptidase 9 substrates by two-dimensional differential in-gel electrophoresis.Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells.Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.An inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivo Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial.Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.The serine protease, dipeptidyl peptidase IV as a myokine: dietary protein and exercise mimetics as a stimulus for transcription and release Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus.The in vivo expression of dipeptidyl peptidases 8 and 9.The dipeptidyl peptidase IV family in cancer and cell biology.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.Recent patents of dipeptidyl peptidase IV inhibitors.Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.A review of gliptins in 2011.Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Cardiovascular effects of gliptins.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].DPP-4 inhibitors: pharmacological differences and their clinical implications.Pharmacokinetic study of saxagliptin in healthy Chinese subjects.Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.

P2860

Q24563430-BCCDD27A-FE1B-43FA-92CC-07ADB97B4105 Q26766089-47618899-4BF4-447D-B14F-F69D4E14C071 Q30426407-796DE737-70C8-4035-AB09-2E948081D768 Q30486745-FD855CF2-BBB3-4F04-A1AC-BCE426896AED Q34004470-AE6C2CD7-04D9-4EA4-A046-84ED9EEB1F6A Q34029715-716D1FA8-FE47-4F69-B514-6864635EFC67 Q34219918-007A134A-0E5D-4D6F-8CBF-B25F5AEA78F1 Q34239784-91AC8796-31FA-4026-ABDB-E1A8556DA3F3 Q34273302-9137C095-C61E-46BC-9BAA-281228D4A385 Q34620486-D1509FFF-8958-43F6-BD22-0458958ED410 Q35026483-8F014855-E835-4B7E-850D-942843FB6F84 Q35040181-1D405CDD-1206-4C12-B04E-CE0C0A7F7419 Q35067242-D2852394-B5CA-4ADB-A8D3-CC063FD828B4 Q35587364-1BA652E5-81AB-4926-B830-38F0FFA79B76 Q35691528-BCDA3459-4391-4C84-933D-EDC543A77306 Q35723683-F8A918BB-29AF-469B-B656-1572D56C7938 Q35916947-F7CECF49-8F1B-484B-9F6E-BABC1481AB4C Q36139126-E4C9FCB7-C70F-49F2-B140-6033D32FC3C9 Q36526318-84B0C08F-3704-46EC-A1A0-F3428EDDA5F2 Q36818849-B637E891-33DC-4DAC-8BA4-88EAFCFDA928 Q36865097-7242EA7D-A9F3-4C3C-A795-6875B55F859F Q37043350-728F7EC8-989C-4C24-997E-C361BE4D0768 Q37193295-0A2F1824-83C0-44CE-8159-4ABAC4CAB028 Q37366826-8862DD4D-1FE8-4CB9-B963-AD2F743CCE2D Q37389403-B0B3D6BE-D1AE-4AE4-9875-60BAA5342DB4 Q37674999-0D2BA3D1-6F4F-4325-A202-AB0FE8A29C19 Q37837059-4A482903-5711-49DB-969C-E4BC3BC7C035 Q37878396-C8067CB3-15C7-429B-BA68-6EC045ED32CE Q37948110-8D08E43D-1C27-48B9-84B2-A0B58BB13447 Q37963451-7CD65389-9E75-49B3-8B63-E0510981D937 Q37965612-CB215930-67B6-4F74-8A43-B41CC0EC1F48 Q37973413-134BBB02-342E-4ADF-A251-C13FC904AD51 Q37992255-45EF7772-AB71-4881-B77D-FABFFE4BF3CA Q38017726-22BEAA9C-08F5-4851-824A-9D2904CCC304 Q38072259-49D3AC09-EB4E-4202-8C09-E9C930113BEA Q38205588-26EE560F-087D-4A3D-81DD-445F4DFB5D5E Q38244576-92490820-9E56-4601-B88F-405CFF257649 Q38470357-D6819D01-4882-444D-A872-52CA367B8886 Q38486819-4C352FBA-3643-4B82-ADEE-C8B4608A348D Q38670397-3E515F35-D131-46C7-B062-EE514BEDC459

P2860

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

http://www.wikidata.org/entity/Q37603371

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

@en

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

@nl

type

label

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

@en

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

@nl

prefLabel

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

@en

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

@nl

P1433

Q37603371-97D91794-9468-4AAA-8402-CD7F16EB96A2

P1476

Q37603371-1C69205D-E341-4455-A030-2BBB018C3B8D

P2093

Q37603371-6A01CBA9-D4FF-49DA-A614-3F422E038992

Q37603371-8709A855-A8DB-4A9D-9960-DDF2D094B815

Q37603371-BFE78428-F63E-4AB6-9C12-6279E43004CD

Q37603371-C818CDDF-AF24-4963-8F16-15A4ADDC0CFF

P2860

Q37603371-00002591-CC88-4D1D-B9AC-FD4E2AB77CCB

Q37603371-0012B901-12F8-481D-8304-C7AAAE22E8B2

Q37603371-11C3DE56-0E27-435D-9BC9-CD2579328123

Q37603371-13DD07D6-668F-4E62-84A7-D221B22845C7

Q37603371-14A817E5-D058-41A7-B679-F3831B81C2C7

Q37603371-1EA46E8A-D517-4076-AEF9-86125445FD30

Q37603371-28535F5F-AD6A-463E-9E9F-AFC149612093

Q37603371-28CEEA78-3C13-46E2-8D35-FD81B4373F62

Q37603371-298D503A-3D16-4E20-BA92-B49EB6A6ADC3

Q37603371-3897D864-C806-4BB0-B3E8-CE13EA2D8899

P304

Q37603371-25416E33-2BA4-4630-AB1E-F5335525DC2F

P31

Q37603371-B6CB02B1-71C0-4F4D-9C83-29D4F6E79592

P356

Q37603371-58E247C6-763B-4C6A-9F53-5DA19AF7DE61

P407

Q37603371-71BD9FEF-5269-4A46-93A4-798234805002

P433

Q37603371-E88CE85F-6E1C-47F3-8BDA-4F21F08726DE

P478

Q37603371-E3CBE8C6-341C-43F7-8A37-A09ED6059218

P577

Q37603371-668A5A32-0C68-4CA6-B509-3A049BFD07C9

P698

Q37603371-2DDD749C-03E5-479F-864D-18EBD2281692

P356

P1433

Clinical Science

P1476

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.

@en

P2093

Denise M T Yu

http://www.w3.org/2001/XMLSchema#string

Mark D Gorrell

http://www.w3.org/2001/XMLSchema#string

Mark Kirby

http://www.w3.org/2001/XMLSchema#string

Steven O'Connor

http://www.w3.org/2001/XMLSchema#string

P2860

Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8

Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection

Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis

P304

31-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/CS20090047

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19780719

http://www.w3.org/2001/XMLSchema#string